8-K: Biote Corp. Settles Litigation with Founder, Repurchases 18.4 Million Shares for $76.9 Million

Biote Corp. has reached a settlement with its founder, Dr. Gary S. Donovitz, involving a $76.9 million share repurchase and the resolution of outstanding litigation.

Summary

• Biote Corp. has entered into a settlement agreement with its founder, Dr. Gary S. Donovitz, to resolve ongoing litigation.
• The agreement includes the repurchase of all 18.4 million shares held by Donovitz for a total of approximately $76.9 million.
• The repurchase will occur over three years, with an initial payment of $32.2 million for 8.2 million shares on April 26, 2024.
• Subsequent repurchases of Paired Interests will occur at the 12, 24, and 36-month anniversaries of the closing date for $15.1 million, $19.1 million, and $10.5 million respectively.
• The settlement also includes a mutual release of claims, termination of the founder advisory agreement, a two-year non-compete agreement for Donovitz, and a voting agreement.
• The average price for the repurchased shares is $4.17 per share.

Sentiment

Score: 7

Explanation: The settlement resolves a legal issue and allows the company to focus on growth, which is positive. However, the cost of the share repurchase is significant and will impact cash flow over three years. The sentiment is therefore moderately positive.

Positives

• The settlement resolves a prolonged and costly legal dispute with the company's founder.
• The share repurchase is expected to be accretive to shareholder value.
• The company's strong capital position and cash generation capability support the repurchase.
• The company can now fully focus on advancing its strategic objectives and driving profitable growth.
• The settlement includes a two-year non-compete agreement with the founder.

Negatives

• The company is spending $76.9 million to repurchase shares from its founder.
• The share repurchase will occur over three years, which may impact cash flow.
• The company is losing the founder's advisory services.

Risks

• The company's success depends on the market acceptance of its dietary supplements.
• The company relies on third parties for the manufacturing of bio-identical hormones.
• The company is sensitive to regulatory, economic, environmental, and competitive conditions.
• The company faces significant competition in its industry.
• The company's growth strategies and acquisitions may not be successful.
• The company is subject to heavy regulatory oversight.
• The company may be impacted by economic, business, and competitive factors, including bank failures.
• Future exchange and interest rates could impact the company.

Future Outlook

The company believes the share repurchase will be accretive to shareholder value and is focused on advancing its strategic objectives and driving profitable growth. The company plans to provide additional details concerning the anticipated financial impacts of the settlement when it reports first quarter financial results on Tuesday, May 7, 2024, after the close of the market.

Management Comments

• Terry Weber, Biote Chief Executive Officer, commented, 'We are pleased to conclude this legal matter, which resolves prolonged and costly litigation.'
• Terry Weber also stated, 'Backed by our strong capital position and cash generation capability, we are well positioned to execute on this multi-year share repurchase that we believe will be accretive to shareholder value.'
• Terry Weber further added, 'With this legal matter behind us, we are fully focused on advancing our strategic objectives and continuing to drive profitable growth.'

Industry Context

This settlement and share repurchase are specific to Biote and its founder, and do not directly reflect broader industry trends. However, it does highlight the importance of managing relationships with key stakeholders and resolving legal disputes efficiently. The company's focus on hormone optimization and therapeutic wellness is part of a growing trend in preventive healthcare.

Comparison to Industry Standards

• Share repurchases are a common method for companies to return value to shareholders, but the specific circumstances of this repurchase are unique to Biote's situation with its founder.
• The multi-year schedule for the repurchase is not typical, as most repurchases are completed within a shorter timeframe.
• The average price of $4.17 per share is a key metric for investors to assess the value of the repurchase.
• It is difficult to compare this specific transaction to industry standards as it is a settlement of a legal dispute and not a typical share buyback program.

Legal Proceedings

• The settlement resolves the previously disclosed litigation with Dr. Gary S. Donovitz.

Related Party Transactions

• The share repurchase from Dr. Gary S. Donovitz is a related party transaction.

Stakeholder Impact

• Shareholders will see a reduction in the number of outstanding shares, which could increase earnings per share.
• The resolution of the litigation removes uncertainty and potential costs.
• The company's focus on growth should benefit employees and other stakeholders.
• The company's cash position will be impacted by the share repurchase.

Next Steps

• The company will complete the share repurchase over the next three years.
• The company will provide additional details on the financial impact of the settlement when it reports first quarter results on May 7, 2024.
• The company will focus on advancing its strategic objectives and driving profitable growth.

Key Dates

Keywords

share repurchase, settlement agreement, litigation, founder, non-compete, biote, BTMD, hormone optimization, preventive health care